Trials / Completed
CompletedNCT02755142
Clinical Study on 5-aminolevulinic Acid Hydrochloride (5-ALA) for Fluorescence-guided Resection of Malignant Gliomas
Clinical Phase I/II Study on 5-aminolevulinic Acid Hydrochloride (5-ALA) for Fluorescence-guided Resection of Malignant Gliomas
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 21 (actual)
- Sponsor
- medac GmbH · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- —
Summary
This study is planned to detect a dose-efficacy relationship between the chosen dose levels of MC506/1 and the extent and quality of fluorescence in the tumour core in patients with newly diagnosed malignant glioma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Gliolan |
Timeline
- Start date
- 2000-02-01
- Primary completion
- 2001-06-01
- Completion
- 2001-06-01
- First posted
- 2016-04-28
- Last updated
- 2016-05-23
Source: ClinicalTrials.gov record NCT02755142. Inclusion in this directory is not an endorsement.